Missouri Valley Cancer Consortium CCOP
密苏里河谷癌症联盟 CCOP
基本信息
- 批准号:6779036
- 负责人:
- 金额:$ 82.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-09-30 至 2007-05-31
- 项目状态:已结题
- 来源:
- 关键词:antineoplastic antibioticsantineoplasticsbehavioral /social science research tagbiliary tract neoplasmblood /lymphatic neoplasmbone neoplasmsbrain neoplasmsbreast neoplasmscancer complicationcancer information systemcancer preventioncancer registry /resourcecancer rehabilitation /careceramideschemopreventionclinical researchclinical trialscolony stimulating factorcommunity health servicescooperative studydata managementesophagus neoplasmestrogensfemale reproductive system neoplasmgastrointestinal neoplasmshead /neck neoplasmhealth services research taghormone therapyhuman subjecthuman therapy evaluationinhalation drug administrationinterferonsinterleukin 2lung neoplasmsmedical outreach /case findingmedical rehabilitation related tagmelanomaneoplasm /cancer chemotherapyneoplasm /cancer educationneoplasm /cancer geneticsneoplasm /cancer immunotherapyneoplasm /cancer palliative treatmentneoplasm /cancer radiation therapyneoplasm /cancer surgeryneoplasm /cancer therapypancreas neoplasmspatient oriented researchprostate neoplasmsseleniumtocopherolstopical drug application
项目摘要
DESCRIPTION (provided by applicant): The Missouri Valley Cancer Consortium
(MVCC) is a community-based research effort with the specific aim of providing
quality cancer care and research opportunities to patients in their respective
communities. This is accomplished primarily through a networking of
physicians, hospitals, and community cancer clinics across Nebraska and Iowa
who recognize the unique needs of people with cancer, and who are committed to
providing cancer care that has an emphasis on research whereby patients may
benefit from cutting-edge technology in the areas of cancer treatment, cancer
control, and cancer prevention. The MVCC serves a catchment area of primarily
Nebraska and Iowa, and through affiliation with nationally recognized research
groups, clinical trials are offered for a wide variety of cancers. A unique
ability to provide clinical trials for cancer prevention and cancer control
enhances the quality of this vital research program. The MVCC has direct
affiliation with the North Central Cancer Treatment Group, Eastern Cooperative
Oncology Group, Radiation Therapy Oncology Group, National Surgical Adjuvant
Breast and Bowel Project, Gynecologic Oncology Group, and Southwest Oncology
Group, is a member of the CTSU, or Clinical Trials Support Unit of the NIH,
receives funding to support the program through an NIH grant as a Community
Clinical Oncology Program (CCOP), and serves a data base of well over 1800
patients who have enrolled in clinical research studies over the years through
their own community medical programs affiliated with MVCC. The MVCC has a
proven track record of producing quality research work from a deeply committed
team of healthcare professionals. Efforts are now being focused on community
awareness of the importance of clinical research participation through
pathways of public education about cancer, along with cancer screening and
cancer prevention programs. Strategies to include minority populations in
these important programs are being utilized as well. The long-term objective
of this vital research program is to provide cancer patients access to
clinical trials in their community, to promote quality cancer care and
education, and to produce research data that will ultimately benefit all
cancer patients.
描述(由申请人提供):密苏里谷癌症协会
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES A MAILLIARD其他文献
JAMES A MAILLIARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES A MAILLIARD', 18)}}的其他基金
相似海外基金
The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
- 批准号:
21K17258 - 财政年份:2021
- 资助金额:
$ 82.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
- 批准号:
499958-2016 - 财政年份:2016
- 资助金额:
$ 82.4万 - 项目类别:
Engage Grants Program
Uhrf1 and the DNA damage response
Uhrf1 和 DNA 损伤反应
- 批准号:
311915 - 财政年份:2013
- 资助金额:
$ 82.4万 - 项目类别:
Studentship Programs
Improvement of RNAi efficacy by blocking RNAi inhibitors
通过阻断 RNAi 抑制剂提高 RNAi 功效
- 批准号:
7109912 - 财政年份:2006
- 资助金额:
$ 82.4万 - 项目类别:
Development of an ICMT Supported Membrane Sensor
ICMT 支持的薄膜传感器的开发
- 批准号:
7037706 - 财政年份:2006
- 资助金额:
$ 82.4万 - 项目类别:
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy
开发 CEES 诱导的皮肤毒性模型并评估水飞蓟宾功效
- 批准号:
7235521 - 财政年份:2006
- 资助金额:
$ 82.4万 - 项目类别:
PhaseI/II Clinical Trial of hHB22.7 anti-CD22 Monoclonal Antibody for Lymphoma
hHB22.7抗CD22单克隆抗体治疗淋巴瘤I/II期临床试验
- 批准号:
7158852 - 财政年份:2006
- 资助金额:
$ 82.4万 - 项目类别:
Mechanism of Formation of Polysulfane Anticancer Agents
聚硫烷抗癌剂的形成机理
- 批准号:
7059750 - 财政年份:2006
- 资助金额:
$ 82.4万 - 项目类别:
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents
α 叶酸受体介导的 GARFTase 抑制剂作为选择性抗肿瘤药物
- 批准号:
7187728 - 财政年份:2006
- 资助金额:
$ 82.4万 - 项目类别:














{{item.name}}会员




